Reaction
Vascular Occlusion reporting signals
As of the last recalculation, Vascular Occlusion appears in 2,084 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is TICAGRELOR (PRR 28.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ticagrelor | 86 | 28.0 | 28.1 |
| Prasugrel Hydrochloride | 17 | 16.8 | 16.9 |
| Methylprednisolone Acetate | 9 | 11.3 | 11.3 |
| Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride | 34 | 11.1 | 11.1 |
| Ranolazine | 11 | 10.6 | 10.6 |
| Clopidogrel | 175 | 9.5 | 9.5 |
| Isosorbide Dinitrate | 15 | 7.7 | 7.7 |
| Fondaparinux Sodium | 6 | 7.4 | 7.4 |
| Heparin Sodium | 10 | 7.3 | 7.3 |
| Insulin Human | 28 | 7.1 | 7.1 |
| Deferasirox | 18 | 6.8 | 6.8 |
| Isosorbide Mononitrate | 13 | 6.3 | 6.3 |
| Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose | 5 | 6.1 | 6.1 |
| Melphalan Hydrochloride | 15 | 6.0 | 6.0 |
| Alirocumab | 15 | 6.0 | 6.0 |
| Alteplase | 9 | 6.0 | 6.0 |
| Nilotinib | 17 | 5.8 | 5.8 |
| Botulinum Toxin Type A | 7 | 5.6 | 5.6 |
| Agalsidase Beta | 5 | 5.4 | 5.4 |
| Romosozumab-Aqqg | 5 | 3.7 | 3.7 |
| Evolocumab | 47 | 2.9 | 2.9 |
| Ranibizumab | 7 | 2.6 | 2.6 |
| Aflibercept | 7 | 2.2 | 2.2 |
| Voxelotor | 3 | 1.3 | 1.3 |